Medication route in out-of-hospital cardiac arrest

Pre-hospitAl RAndomised trial of MEDICation route in out-of-hospital cardiac arrest (PARAMEDIC3)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14223494

Enrollment

15000

Registered

2021-08-16

Start date

2021-11-12

Completion date

Unknown

Last updated

2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac arrest Circulatory System Cardiac arrest

Interventions

INTERVENTIONS Patients will be randomly allocated to receive either IO first strategy (intervention) or IV first strategy (control) through us of opaque, sequentially numbered sealed envelopes (or an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Out-of-hospital cardiac arrest currently receiving cardiopulmonary resuscitation 2. Requirement for vascular access to administer cardiac arrest drugs

Exclusion criteria

Exclusion criteria: 1. Children (known or appear to be <18 years) 2. Known or apparent pregnancy 3. Already have vascular access

Design outcomes

Primary

Measure	Time frame
Survival at 30 days following randomisation measured using patient records	—

Secondary

Measure	Time frame
Measured using patient records unless specified: 1. Return of spontaneous circulation and time to return of spontaneous circulation at any time follwoing randomisation 2. Survived event (sustained return of spontaneous circulation) (yes/no) at hospital handover 3. Survival at hospital discharge, 3 and 6 months following randomisation 4. Neurological function (measured by modified Rankin Scale) at hospital discharge, 3 and 6 months following randomisation 5. Health related quality of life (measured by EQ-5D-5L) at 3 and 6 months following randomisation 6. Hospital length of stay 7. Critical care length of stay	—

Measure

Time frame

Measured using patient records unless specified: 1. Return of spontaneous circulation and time to return of spontaneous circulation at any time follwoing randomisation 2. Survived event (sustained return of spontaneous circulation) (yes/no) at hospital handover 3. Survival at hospital discharge, 3 and 6 months following randomisation 4. Neurological function (measured by modified Rankin Scale) at hospital discharge, 3 and 6 months following randomisation 5. Health related quality of life (measured by EQ-5D-5L) at 3 and 6 months following randomisation 6. Hospital length of stay 7. Critical care length of stay

—

Countries

England, United Kingdom, Wales

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026